LONDON--(BUSINESS WIRE)--Inventages announces that one of its portfolio companies, Cognoptix, has demonstrated unprecedented accuracy in detecting Alzheimer’s disease. A multi-site clinical trial of the SAPPHIRE II eye test showed a sensitivity of 85% and a specificity of 95% in differentiating Alzheimer’s disease patients from healthy volunteers. The Cognoptix test involves a simple eye test that detects beta-amyloid, the hallmark of Alzheimer’s disease. This test is significantly differentiated from other blood or imaging tests in being: Simple and non-invasive to perform
Help employers find you! Check out all the jobs and post your resume.
